Komipharm International Co., Ltd. (KOSDAQ:041960)
 6,040.00
 -20.00 (-0.33%)
  Oct 31, 2025, 3:30 PM KST
Komipharm International Revenue
Komipharm International had revenue of 13.68B KRW in the quarter ending June 30, 2025, a decrease of -28.59%. This brings the company's revenue in the last twelve months to 54.81B, up 6.68% year-over-year. In the year 2024, Komipharm International had annual revenue of 58.78B with 37.83% growth.
Revenue (ttm) 
 54.81B
Revenue Growth 
 +6.68%
P/S Ratio 
 7.95
Revenue / Employee 
 340.45M
Employees 
 161
Market Cap 
435.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 58.78B | 16.13B | 37.83% | 
| Dec 31, 2023 | 42.65B | 2.85B | 7.15% | 
| Dec 31, 2022 | 39.80B | 3.95B | 11.03% | 
| Dec 31, 2021 | 35.85B | -1.31B | -3.53% | 
| Dec 31, 2020 | 37.16B | 1.67B | 4.71% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |